4D Molecular Therapeutics (FDMT) has an average rating of buy and mean price target of $28.67, according to analysts polled by FactSet.
Price: $10.27, Change: $+0.20, Percent Change: +1.99%
What else is happening in Research?
Research
Oppenheimer Downgrades Capricor Therapeutics to Perform From Outperform, Price Target is $54
Capricor Therapeutics (CAPR) has an average rating of overweight and mean price target of $29.35, according to analysts polled by FactSet.Price: $3.00, Change: $-3.57, Percent Change: -54.34%
$CAPR
Research
BofA Securities Downgrades Cincinnati Financial to Neutral From Buy, Lowers Price Target to $193 From $197
Cincinnati Financial (CINF) has an average rating of overweight and mean price target of $190, according to analysts polled by FactSet.Price: $179.11, Change: $-2.23, Percent Change: -1.23%
$CINF
Research
RBC Cuts Price Target on Wingstop to $200 From $225, Keeps Outperform Rating
Wingstop (WING) has an average rating of buy and mean price target of $214.62, according to analysts polled by FactSet.
$WING